Omapatrilat- the story of OVERTURE and OCTAVE

International Journal of Cardiology

Volumn 86, Issue 1, 2002, Pages 1-4

  Coats, Andrew J S ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Angiotensin converting enzyme inhibitor; Heart failure; Hypertension; Natriuretic peptides; Octave trial; Omapatrilat; Overture trial; Randomised controlled trial; Survival; Vasopeptidase inhibition

Indexed keywords

ATENOLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; OMAPATRILAT;

ANGIONEUROTIC EDEMA; CARDIOLOGY; CLINICAL TRIAL; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; MEDICAL LITERATURE; MORTALITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0036828336     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(02)00389-3     Document Type: Editorial

References (20)

1. http://www.VPI-CME.com accessed June 1 2002.
2. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedersen O., Lindholm L.H., Nieminen M.S., Omvik P., Oparil S., Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 359:(9311):2002;995-1003.
3. Lindholm L.H., Ibsen H., Dahlof B., Devereux R.B., Beevers G., de Faire U., Fyhrquist F., Julius S., Kjeldsen S.E., Kristiansson K., Lederballe-Pedersen O., Nieminen M.S., Omvik P., Oparil S., Wedel H., Aurup P., Edelman J., Snapinn S. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 359:(9311):2002;1004-1010.
4. van Veldhuisen D.J., Poole-Wilson P.A. The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure. Int J Cardiol. 80:(1):2001;19-27.
5. Coats A.J. Consumer involvement in cardiovascular research: ways to combat bias and secrecy. Int J Cardiol. 75:(1):2000;1-3.
6. Coats A.J. Heart Failure 99 - the MOXCON story. Int J Cardiol. 71:(2):1999;109-111.
7. Omapatrilat. Drugs. 1999;1(4):350-351.
8. Campese V.M., Lasseter K.C., Ferrario C.M., Smith W.B., Ruddy M.C., Grim C.E., Smith R.D., Vargas R., Habashy M.F., Vesterqvist O., Delaney C.L., Liao W.C. Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients. Hypertension. 38:(6):2001;1342-1348.
9. Coats A.J. Omapatrilat - the ups and downs of an exciting but complicated new drug. Int J Cardiol. 74:(1):2000;1-3.
10. Lapointe N., Blais C., Adam A., Parker T., Sirois M.G., Gosselin H., Clement R., Rouleau J.L. Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat. J Am Coll Cardiol. 39:(10):2002;1692-1698.
11. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, Porter CB, Proulx G, Qian C, Block AJ. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000;356(9230):615-20; Erratum in: Lancet 2000;356(9243):1774.
12. Blais C. Jr., Lapointe N., Rouleau J.L., Clement R., Gervais N., Geadah D., Adam A. Effects of the vasopeptidase inhibitor omapatrilat on cardiac endogenous kinins in rats with acute myocardial infarction. Peptides. 22:(6):2001;953-962.
13. Tabrizchi R. Omapatrilat. Bristol-Myers Squibb. Curr Opin Investig Drugs. 2:(10):2001;1414-1422.
14. Kostis J.B., Cobbe S., Johnston C., Ford I., Murphy M., Weber M.A., Black H.R., Plouin P.F., Levy D., Mancia G., Larochelle P., Kolloch R.E., Alderman M., Ruilope L.M., Dahlof B., Flack J.M., Wolf R. OPERA Study Group. Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events. Design of the Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial. Am J Hypertens. 15:(2 Pt 1):2002;193-198.
15. Coats A.J. Cardiovascular research in the dock: a case for the defence. Int J Cardiol. 75:(2-3):2000;121-122.
16. McIntyre H.D. National service framework heart failure. Int J Cardiol. 74:(2-3):2000;241-242.
17. http://www.VPI-CME.com accessed June 1 2002.
18. Angioedema due to ACE inhibitors: Common and inadequately diagnosed. Prescrire Int 1998;7(35):92-93.
19. Agostoni A., Cicardi M., Cugno M., Zingale L.C., Gioffre D., Nussberger J. Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology. 44:(1-2):1999;21-25.
20. Nussberger J., Cugno M., Amstutz C., Cicardi M., Pellacani A., Agostoni A. Plasma bradykinin in angio-oedema. Lancet. 351:(9117):1998;1693-1697.